Targeted Anticancer

Question 1

Target of Bevacizumab

Answer 1

VEGF

Question 2

2 TKI’s associated with cardiovascular dysfunction

Answer 2

Lapatinib, Nilotinib

Question 3

Administration of Bortezomib

Answer 3

IV Bolus or SC Injection

Question 4

All currently available Tyrosine Kinases inhibitors work by

Answer 4

Binding to the highly-conserved ATP-binding site

Question 5

Bevacizumab Toxicities

Answer 5

HTN, CHR, Pulmonary Hemorrhage, GI perforation

Question 6

Block heterodimerization of Her2 and Her3

Answer 6

MOA of Pertuzumab

Question 7

Blood dyscriasis should be immediately associated with

Answer 7

Cytotoxic Agents

Question 8

Function of 26-S proteosome

Answer 8

Inhibit degradation of proteins marked by ubiquitin

Question 9

MOA of Everolimus

Answer 9

mTOR inhibitor

Question 10

MOA of Ipiliumumab

Answer 10

Stimuates T-Cell activation by binding CTLA-4 on surface

Question 11

MOA of Pertuzumab

Answer 11

Block heterodimerization of Her2 and Her3

Question 12

MOA of Sirolimus

Answer 12

mTOR inhibitor

Question 13

MOA of Temsirolimus

Answer 13

mTOR inhibitor

Question 14

mTOR inhibitors

Answer 14

Sirolimus, Everolimus, Temsirolimus

Question 15

Patients with mutations in KRAS and BRAF are less likely to respond to

Answer 15

Anti-EGFR therapies

Question 16

Prevents binding of first generation tyrosine kinase inhibitors

Answer 16

Significance of T315I mutation

Question 17

Significance of T315I mutation

Answer 17

Prevents binding of first generation tyrosine kinase inhibitors

Question 18

Stimuates T-Cell activation by binding CTLA-4 on surface

Answer 18

MOA of Ipiliumumab

Question 19

Target of Bortezomib

Answer 19

26-S Proteosome

Question 20

Target of Cetuximab

Answer 20

EGFR

Question 21

Target of Ipilumumab

Answer 21

CTLA-4

Question 22

Target of Ofatumumab

Answer 22

CD20

Question 23

Target of Panitumumab

Answer 23

EGFR

Question 24

Target of Rituximab

Answer 24

CD20

Question 25

Target of Trastuzumab

Answer 25

Her-2

Question 26

TKI inhibitors w/ common Thyroid Dysfunction

Answer 26

Sorafenib, Sunitibin, Imatinib

Question 27

Toxicities of Cetuximab

Answer 27

Infusion, skin rash with sun

Question 28

Toxicities of Ofatumumab

Answer 28

Infusion reaction, Infections, Progressive Leukoencephalopathy

Question 29

Toxicities of Rituximab

Answer 29

Infusion reaction, B-cell depletion, Lymphopenia

Question 30

Toxicities of Trastuzumab

Answer 30

Cardiomyopathy, (infusion reaction)

Question 31

Transcription factor that induces VEGF

Answer 31

HIF-1

Question 32

What targets 26-S Proteosome

Answer 32

Bortezomib

Question 33

What targets CD20

Answer 33

Rituximab, Ofatumumab

Question 34

What targets CTLA-4

Answer 34

Ipilumumab

Question 35

What targets EGFR

Answer 35

Cetuximab, Panitumumab

Question 36

What targets Her-2

Answer 36

Trastuzumab

Question 37

What targets VEGF

Answer 37

Bevacizumab

Question 38

What to monitor with TKI's

Answer 38

Thyroid Function, Bone Density, Blood Glucose in Diabetics